Moderna Shares Jump 6.5% as FDA Sets August Deadline for mRNA-1010 Flu Vaccine

Moderna Inc. shares jumped 6.5% to reach $47 following a regulatory breakthrough regarding its seasonal flu vaccine candidate, mRNA-1010. The U.S. Food and Drug Administration (FDA) reversed its previous refusal to review the vaccine after a successful "Type A" meeting between the company and regulators. This pivotal meeting resolved outstanding concerns, leading the FDA to establish a formal decision deadline for August 5. The reversal marks a critical strategic milestone for Moderna as it seeks to diversify its mRNA portfolio beyond COVID-19 products. Investors cheered the newfound clarity on the regulatory timeline, which significantly improves the prospects for commercialization and steady revenue streams. The company remains focused on leveraging its innovative technology to address a broader range of respiratory illnesses and expand its global market presence.